MBX Biosciences, Inc. (MBX:NASDAQ) closed at $48.50 on October 23, 2026, down 3.88% on the day. The stock trades 33.2% below its 52-week high of $72.64 and 203.9% above its 52-week low of $15.96. Over the past year, it gained 185.3%. MBX Biosciences, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, MBX closed higher on 131 days (52%). Its best day was June 11, 2026 (+20.20%) and its worst was January 23, 2026 (-10.71%). The stock moved 10% or more in a single session 11 times.
MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders. Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. We designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration.
Find more stocks like MBX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.